{"title":"Integrilin, Intervention, and the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy Trial.","authors":"Thel","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Eptifibatide (Integrelin, Corr Therapeutics, South San Francisco, CA) is a cyclic heptapeptide competitive inhibitor of the platelet glycoprotein (GP) IIb/IIIa receptor that has a short half-life. The results of the initial dose-finding and phase III trials are reviewed and the ongoing Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial are described.</p>","PeriodicalId":80270,"journal":{"name":"Current interventional cardiology reports","volume":"1 4","pages":"339-345"},"PeriodicalIF":0.0000,"publicationDate":"1999-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current interventional cardiology reports","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Eptifibatide (Integrelin, Corr Therapeutics, South San Francisco, CA) is a cyclic heptapeptide competitive inhibitor of the platelet glycoprotein (GP) IIb/IIIa receptor that has a short half-life. The results of the initial dose-finding and phase III trials are reviewed and the ongoing Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial are described.
eptifitide (integrinin, Corr Therapeutics, South San Francisco, CA)是一种半衰期短的血小板糖蛋白(GP) IIb/IIIa受体的环七肽竞争性抑制剂。本文回顾了初始剂量发现和III期试验的结果，并描述了正在进行的整合素治疗对血小板IIb/IIIa受体的增强抑制(ESPRIT)试验。
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
